Form 4: Pacific Biosciences Director Receives Stock Option Grant

Director Christopher M. Smith was granted 223,492 stock options in Pacific Biosciences of California, Inc. on June 3, 2026.

Summary

• Director Christopher M. Smith received a grant of 223,492 stock options.
• The options have an exercise price of $1.58 per share.
• The grant date is June 3, 2026, with an expiration date of June 3, 2036.
• The options vest monthly over a one-year period, contingent on continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The use of monthly vesting over one year for director equity is consistent with standard compensation practices for mid-cap biotechnology firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on a monthly basis starting July 3, 2026.

Key Dates

Keywords

PACB, Pacific Biosciences, Form 4, Insider Trading, Stock Options, Director Compensation